Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1, demonstrating sustained safety and efficacy profiles in managing recurrent or metastatic cervical cancer. This therapeutic antibody shows promising potential in treating additional oncological indications, including small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma. Its mechanism involves the inhibition of the PD-1/PD-L1 pathway, a critical axis in tumor immune evasion, thereby enhancing anti-tumor immune responses. Socazolimab is under investigation for its versatility and effectiveness across a broad spectrum of cancer types.
Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1, demonstrating sustained safety and efficacy profiles in managing recurrent or metastatic cervical cancer. This therapeutic antibody shows promising potential in treating additional oncological indications, including small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma, and osteosarcoma. Its mechanism involves the inhibition of the PD-1/PD-L1 pathway, a critical axis in tumor immune evasion, thereby enhancing anti-tumor immune responses. Socazolimab is under investigation for its versatility and effectiveness across a broad spectrum of cancer types.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
